Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S2W-03767 · Session 2

Whether Ebixa (memantine) is being routinely prescribed for the treatment of moderately severe to severe Al'heimer's disease.

Answered Asked by Dr Sylvia Jackson Lab Lodged 30 Oct 2003

The question

To ask the Scottish Executive whether Ebixa (memantine) is being routinely prescribed for the treatment of moderately severe to severe Al'heimer's disease.

The answer

Answered by Malcolm Chisholm on 12 Nov 2003 · 13 days after it was lodged, on time

In August 2003, the ScottishMedicines Consortium (SMC) considered memantine (Ebixa) and on the evidencesubmitted by the manufacturer did not recommend it for use in NHSScotland. Weunderstand from the SMC that they have been in touch with the manufacturer andexpect a resubmission.
SMC advice does not overridethe individual responsibility of health professionals to make appropriatedecisions in the circumstances of the individual patient. Prescription data forJanuary to August 2003 (the latest available data) show that a total of 1,205prescribed items for memantine were dispensed by community pharmacists anddispensing doctors in Scotland. Data on prescriptions dispensed by hospitals orhospital-based clinics are not available centrally.

In the Official Report

No contribution in the Official Report cites S2W-03767 by reference.